Literature DB >> 1192356

Successful transurethral intralesional BCG therapy of a bladder melanoma.

J B deKernion, S H Golub, R K Gupta, M Silverstein, D L Morton.   

Abstract

An isolated metastasis of malignant melanoma to the urinary bladder of a patient was sucessfully eradicated by transurethral intralesional injection of BCG. Total destruction of the tumor was confirmed by subsequent excision. Lymphocyte blastogenesis studies revealed no significant alteration in immunocompetence secondary to the therapy, except for an increased responsiveness to PPD. There was no evidence of presence of blocking factors following therapy; cytotoxicity against MLA-14 melanoma cells sharply increased after the intralesional injection. Humoral antimelanoma antibody levels, determined by complement fixation, were decreased before the intralesional therapy, but increased markedly immediately following the transurethral BCG injection.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1192356     DOI: 10.1002/1097-0142(197511)36:5<1662::aid-cncr2820360520>3.0.co;2-6

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

Review 1.  In situ vaccination with nanoparticles for cancer immunotherapy: understanding the immunology.

Authors:  Chenkai Mao; Michael-Joseph Gorbet; Akansha Singh; Ashish Ranjan; Steven Fiering
Journal:  Int J Hyperthermia       Date:  2020-12       Impact factor: 3.914

Review 2.  Effects of Mycobacterium bovis Calmette et Guérin (BCG) in oncotherapy: Bladder cancer and beyond.

Authors:  Neelam Mukherjee; Esther Julián; Jordi B Torrelles; Robert S Svatek
Journal:  Vaccine       Date:  2021-10-07       Impact factor: 4.169

Review 3.  Mechanisms of action of bacillus Calmette-Guérin in the treatment of superficial bladder cancer.

Authors:  J J Patard; D K Chopin; L Boccon-Gibod
Journal:  World J Urol       Date:  1993       Impact factor: 4.226

4.  Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes.

Authors:  Donald L Morton; Eddy C Hsueh; Richard Essner; Leland J Foshag; Steven J O'Day; Anton Bilchik; Rishab K Gupta; Dave S B Hoon; Mepur Ravindranath; J Anne Nizze; Guy Gammon; Leslie A Wanek; He-Jing Wang; Robert M Elashoff
Journal:  Ann Surg       Date:  2002-10       Impact factor: 12.969

Review 5.  Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy.

Authors:  Yuan-qiang Zheng; Youssef W Naguib; Yixuan Dong; Yan-chun Shi; Shorgan Bou; Zhengrong Cui
Journal:  Expert Rev Vaccines       Date:  2015       Impact factor: 5.217

Review 6.  Melanoma of the urinary bladder: a review of the literature.

Authors:  Anthony Kodzo-Grey Venyo
Journal:  Surg Res Pract       Date:  2014-01-12

7.  Conservative management of primary malignant melanoma of the bladder: a case report.

Authors:  Sebastiano Rapisarda; Maida Bada; Andrea Polara; Felice Crocetto; Massimiliano Creta; Francesco Chiancone; Massimo Occhipinti; Rossella Bertoloni; Armando Marciano; Luca Aresu; Arjan Nazaraj; Sara Grosso; Gaetano Grosso
Journal:  J Med Case Rep       Date:  2021-02-05

Review 8.  100 years of Bacillus Calmette-Guérin immunotherapy: from cattle to COVID-19.

Authors:  Niyati Lobo; Nathan A Brooks; Alexandre R Zlotta; Jeffrey D Cirillo; Stephen Boorjian; Peter C Black; Joshua J Meeks; Trinity J Bivalacqua; Paolo Gontero; Gary D Steinberg; David McConkey; Marko Babjuk; J Alfred Witjes; Ashish M Kamat
Journal:  Nat Rev Urol       Date:  2021-06-15       Impact factor: 14.432

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.